InnoCare Doses First Subject in Phase 1 Trial of Autoimmune Drug ICP-B161 in China

• InnoCare Pharma dosed the first subject in a Phase 1 trial of ICP-B161 in China on Oct. 30, 2026.
• The bispecific antibody targets TL1A and IL-23p19 for potential treatment of autoimmune diseases, including inflammatory bowel disease.
• Preclinical studies showed significant reductions in colitis-related symptoms with good tolerability.
• Its extended half-life supports less frequent dosing and subcutaneous administration.
• No bispecific antibody targeting both TL1A and IL-23p19 has been approved worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610292201PRIMZONEFULLFEED9856744) on October 30, 2026, and is solely responsible for the information contained therein.